Recomendaciones de la asociación colombiana de nefrología en trasplante renal durante la pandemia por coronavirus (covid-19)

Resumen

La Asociación Colombiana de Nefrología (ASOCOLNEF), conform´ó un grupo de trabajo para el desarrollo de recomendaciones por consenso de expertos en el manejo en trasplante renal durante la pandemia. Estas recomendaciones son dirigidas al personal de salud a nivel nacional (Colombia), y están elaboradas con base a las guías internacionales y a los reportes en la literatura de pacientes trasplantados  renales con infección por Covid 19, disponibles a la fecha de elaboración de la misma. La información disponible es limitada, motivo por el cual no es posible asignar nivel de evidencia a la mayor parte de recomendaciones sobre el comportamiento de esta enfermedad en la población con trasplante renal. Debido a la dinámica de crecimiento de la pandemia a nivel mundial y en Colombia, y a la publicación de nueva evidencia con respecto al comportamiento clínico y el manejo en población trasplantada, es posible que este documento tenga actualizaciones  posteriores.

Descargas

La descarga de datos todavía no está disponible.

Referencias

1. Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Degli Antoni A, et al. COVID-19 in Kidney Transplant Recipients. Am J Transplant [Internet]. 2020;1–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32233067
2. Quinta Newsletter del Registro Covid 19 de la Sociedad Española de Nefrologia. abril 2020
3. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-CoV2/COVID-19 en establecimientos de atención en salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Revista de la Asociación colombiana de infectología. Infectio. Volumen 24 Número 3 (S1). Marzo 2020.
4. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html
5. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant [Internet]. 2020 Apr 16; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32301155
6. Pereira M, Mohan S, Cohen D, ey al. Covid 19 in organ transplants recipients: initial report from the US epicenter. 2020
7. Columbia University Kidney Transplant Program. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. J Am Soc Nephrol [Internet]. 2020 Apr 21; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32317402
8. Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, et al. Covid-19 and Kidney Transplantation. N Engl J Med [Internet]. 2020 Apr 24; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32329975
9. Su H, Yang M, Wan Ch, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID 19 in China. Kidney Int 2020.
10. Guan W, NI Z, HU Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. 11/04/2020 disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa2002032
11. Fishman JA, Grossi PA. Novel Coronavirus-19 (COVID-19) in the Immunocompromised Transplant Recipient: #Flatteningthecurve. Am J Transplant. el 31 de marzo de 2020.
12. Zhang H, Chen Y, Yuan Q, Xia Q-X, Zeng X-P, Peng J-T, et al. Identification of Kidney Transplant Recipients with Coronavirus Disease 2019. Eur Urol [Internet]. 2020;1–6. Disponible en: https://doi.org/10.1016/j.eururo.2020.03.030
13. Guillen E, Pineiro GJ, Revuelta I, Rodriguez D, Bodro M, Moreno A, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Am J Transplant. 2020;(March):1–4.
14. Romanelli A; Mascolo S. Inmmunosuppresion drug- related and clinical manifestations of coronavirus disease 2019 a therapeutical hypothesis [INTERNET] [consultado en: 11 de Abril 2020] disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.15905.
15. American Society of Transplantation, updated marzo 16 de 2020. https://optn.transplant.hrsa.gov/news/information-fortransplant-programs-and-opos-regarding-2019-novel-coronavirus
16. Ahn C, Amer H, Anglicheau D, Ascher N, Baan C, Bat-Ireedui B, et al. Global Transplantation COVID Report March 2020. Transplantation. 2020. 1 p.
17. Boëlle PY, Souty C, Launay T, Guerrisi C, Turbelin C, Behillil S, et al. Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020. Euro Surveill. el 1 de abril de 2020;25(14).
18. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Vol. 7, Military Medical Research. BioMed Central Ltd.; 2020.
19. Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;0–3.
20. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. Early experience of COVID -19 infection in kidney transplant patients - Italian experience *. Kidney Int [Internet]. 2020; Disponible en: https://doi.org/10.1016/j.kint.2020.04.002
21. Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients—report of 2 cases. Am J Transplant. 2020;00:1–3. https://doi.org/10.1111/ajt.15896
22. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020;395(10229):1033–4. Disponible en: http://dx.doi.org/10.1016/S0140-6736(20)30628-0
23. Chan JFW, Yao Y, Yeung M-L, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset Downloaded from [Internet]. Vol. 5, Journal of Infectious Diseases Advance Access. 2015. Disponible en: http://jid.oxfordjournals.org/
24. Willicombe M, Thomas D, Mcadoo S. COVID-19 and Calcineurin Inhibitors : Should They Get Left Out in the Storm ? 2020;1–2.
25. Carbajo-Lozoya J, Ma-Lauer Y, Malešević M, Theuerkorn M, Kahlert V, Prell E, et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res. el 12 de mayo de 2014;184:44–53.
26. Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, Von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165(1):112–7.
27. Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Vol. 15, Expert Opinion on Drug Safety. Taylor and Francis Ltd; 2016. p. 303–19.
28. Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Vol. 2013, Clinical and Developmental Immunology. 2013
29. Huang CT, Hung CY, Chen TC, et al. Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model. Scientifics Reports. 2017; 7:4136.
30. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit Care Med. 2020;48(2):e98–106.
31. Ma Y, Diao B, Lv X, Zhu J, Liang W, Liu L, et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. Disponible en: https://doi.org/10.1101/2020.02.24.20027201
32. Rosselli D. Análisis a partir de datos oficiales en Colombia. Abril 2020.
33. Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2. Ther Drug Monit [Internet]. abril de 2020;1. Disponible en: http://journals.lww.com/10.1097/FTD.0000000000000761
34. Patel AN, Desai SS, David ;, Grainger W, Mehra MR. Usefulness of Ivermectin in COVID-19 Illness.
35. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. el 1 de junio de 2020;178
36. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. el 28 de marzo de 2020.
37. López V, Vázquez T, Alonso-Titos J, Cabello M, Alonso A, Beneyto I, et al. Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal. Nefrología. abril de 2020;
38. World Health Organization (WHO). Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases [Internet]. 2020. Available from: https://apps.who.int/iris/handle/10665/331329
39. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. el 23 de enero de 2020;25(3).
40. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem [Internet].
41. U.S. Department of Health & Human Services (2020) Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus. 24 Jan 2020. En: https:// www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for- detection-instructions.pdf. 2014.
42. Ogimi C, Greninger AL, Waghmare AA, Kuypers JM, Shean RC, Xie H, et al. Prolonged shedding of human coronavirus in hematopoietic cell transplant recipients: Risk factors and viral genome evolution. J Infect Dis. el 15 de julio de 2017;216(2):203–9.
43. Liu L, Liu W, Wang S, Zheng S. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv. 2020 Mar 8;2020.03.06.20031856.
44. Ferritin D, Troponin ESRLDH, Ecg B, Cxr P, Il- P. COVID19 MGH treatment guidance 031820.pdf. 2020.
45. 1. Sociedad Española de Nefrología. https://www.senefro.org. [En línea] 2020.https://mailchi.mp/senefro/registro-epidemiolgico-vhc-vhb-vih-1314533
46. ERA EDTA. The ERA-EDTA COVID-19 Database for patients on kidney replacement therapy. [En línea] 15 de 04 de 2020. https://www.era-edta.org/en/wp-content/uploads/2020/04/ERACODA_Study_Report_2020-04-15.pdf.
47. as: Prachand VN. Medically Necessary, Time-Sensitive Procedures: Scoring Systemto Ethically and Efficiently Manage Resource Scarcity and Provider Risk During the COVID-19Pandemic, Journal of the American College of Surgeons (2020), doi: https://doi.org/10.1016/j.jamcollsurg.2020.04.011
48. American College of Surgeons. www.facs.org. [En línea] 30 de 03 de 2020. https://www.facs.org/-/media/files/covid19/considerations_optimum_surgeon_protection.ashx.
49. Ministerio de Salud. https://www.minsalud.gov.co. [En línea] 2020. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/tabla-epp-consenso.pdf.
Publicado
2020-04-30
Cómo citar
1.
Torres RE, Montero C, Benavides C, Malaver N, García Padilla P, Acevedo A, Olivares Algarin O, Hernández A. Recomendaciones de la asociación colombiana de nefrología en trasplante renal durante la pandemia por coronavirus (covid-19) . Rev. Colomb. Nefrol. [Internet]. 30 de abril de 2020 [citado 4 de junio de 2020];7(Supl 2). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/447
Sección
Artículo de revisión